Stock Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of some unusual options trading on Wednesday. Stock investors bought 1,002 put options on the company. This represents an increase of 1,791% compared to the typical volume of 53 put options.

Insider Activity at Maravai LifeSciences

In other news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $9.81, for a total transaction of $97,520,954.94. Following the completion of the transaction, the director now directly owns 20,150,005 shares of the company’s stock, valued at approximately $197,671,549.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.63% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in Maravai LifeSciences by 310.2% during the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after purchasing an additional 2,711 shares during the period. Gladius Capital Management LP bought a new stake in shares of Maravai LifeSciences in the fourth quarter valued at about $30,000. Headlands Technologies LLC bought a new position in Maravai LifeSciences during the first quarter worth about $42,000. Performa Ltd US LLC raised its stake in Maravai LifeSciences by 112.4% in the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock worth $39,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Blue Trust Inc. acquired a new stake in Maravai LifeSciences during the second quarter worth approximately $44,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Trading Up 2.8 %

MRVI opened at $8.51 on Friday. The firm has a 50 day simple moving average of $8.42 and a 200 day simple moving average of $7.79. Maravai LifeSciences has a fifty-two week low of $4.52 and a fifty-two week high of $12.10. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -8.60 and a beta of 0.02. The company has a debt-to-equity ratio of 0.71, a current ratio of 11.32 and a quick ratio of 10.47.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Wednesday, May 8th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.28%. The business had revenue of $64.18 million for the quarter, compared to the consensus estimate of $60.84 million. On average, sell-side analysts anticipate that Maravai LifeSciences will post -0.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on MRVI shares. Craig Hallum began coverage on shares of Maravai LifeSciences in a research note on Wednesday, April 10th. They issued a “buy” rating and a $15.00 target price on the stock. Robert W. Baird raised their price objective on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Thursday, May 9th. Finally, The Goldman Sachs Group decreased their price target on Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Maravai LifeSciences currently has an average rating of “Moderate Buy” and an average target price of $11.44.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.